Inner Circle Fund Cambiar Aggressive Value ETF (CAMX)

N/A +N/A (N/A)
Market Cap N/A
Revenue (ttm) N/A
Net Income (ttm) N/A
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume N/A
Avg Vol N/A
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K N/A
Beta N/A
Analysts N/A
Price Target N/A

Company Profile

Under normal circumstances, the fund primarily invests in equity securities of companies located in the United States. The fund typically invests in a portfolio of 20-30 issuers that Cambiar Investors, the fund’s investment adviser, believes represent the best opportunities for long-term capital appreciation. The fund is non-diversified.

Phone: 855-842-3863
OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 10:56 PM
$CAMX RSI: 73.10, MACD: 0.5465 Vol: 0.80, MA20: 32.80, MA50: 32.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 25 at 2:17 PM
Camurus ($CAMX) scores a CHMP recommendation for Oczyesa in acromegaly – a major step toward EU approval. With superior efficacy vs. placebo and a patient-friendly monthly self-injection, this could disrupt the standard of care. Final EC decision expected imminently. High stakes for a rare disease market. https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-oczyesa-for-treatment-of-acromegaly-in-the-eu-302438435.html
0 · Reply
Latest News on CAMX
Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

Jan 9, 2026, 9:36 AM EST - 4 months ago

Camurus announces FDA acceptance of NDA resubmission for Oclaiz™ for the treatment of acromegaly

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Jul 15, 2024, 1:48 AM EDT - 1 year ago

Camurus announces positive Phase 3 results from the ACROINNOVA 2 study of octreotide SC depot (CAM2029) in acromegaly patients

Cambiar Investors Launches Aggressive Value ETF

Feb 15, 2023, 9:00 AM EST - 3 years ago

Cambiar Investors Launches Aggressive Value ETF

OfficialStocktwitsUser
OfficialStocktwitsUser May. 5 at 10:56 PM
$CAMX RSI: 73.10, MACD: 0.5465 Vol: 0.80, MA20: 32.80, MA50: 32.16 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Rage_Against_The_Machine
Rage_Against_The_Machine Apr. 25 at 2:17 PM
Camurus ($CAMX) scores a CHMP recommendation for Oczyesa in acromegaly – a major step toward EU approval. With superior efficacy vs. placebo and a patient-friendly monthly self-injection, this could disrupt the standard of care. Final EC decision expected imminently. High stakes for a rare disease market. https://www.prnewswire.com/news-releases/chmp-recommends-approval-of-oczyesa-for-treatment-of-acromegaly-in-the-eu-302438435.html
0 · Reply